Puma Biotechnology Inc Common Stock PBYI
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T13:44:26.765Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T09:41:10.421289491Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T13:44:26.427267+00:00
Puma Biotechnology Inc Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 7.86 | 416.9% | 28.2% | |||
| 40Δ | 8.30 | 384.9% | 24.4% | |||
| 45Δ | 8.71 | 251.0% | 20.0% | 8.74 | 352.9% | 20.6% |
| 50Δ | 8.45 | 276.2% | 19.4% | 9.18 | 320.9% | 16.7% |
| 55Δ | 8.18 | 301.4% | 18.9% | 9.62 | 288.9% | 12.9% |
| 60Δ | 7.92 | 326.6% | 18.3% | 10.05 | 259.4% | 9.4% |
| 65Δ | 7.66 | 351.7% | 17.8% | 10.43 | 244.5% | 8.1% |
| 70Δ | 10.80 | 229.6% | 6.7% | |||
| 75Δ | 11.18 | 214.7% | 5.4% | |||
| 80Δ | 11.55 | 199.8% | 4.0% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.86
- IV
- 416.9%
- B/E move
- 28.2%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.30
- IV
- 384.9%
- B/E move
- 24.4%
45Δ
- Pseudo strike
- 8.71
- IV
- 251.0%
- B/E move
- 20.0%
- Pseudo strike
- 8.74
- IV
- 352.9%
- B/E move
- 20.6%
50Δ
- Pseudo strike
- 8.45
- IV
- 276.2%
- B/E move
- 19.4%
- Pseudo strike
- 9.18
- IV
- 320.9%
- B/E move
- 16.7%
55Δ
- Pseudo strike
- 8.18
- IV
- 301.4%
- B/E move
- 18.9%
- Pseudo strike
- 9.62
- IV
- 288.9%
- B/E move
- 12.9%
60Δ
- Pseudo strike
- 7.92
- IV
- 326.6%
- B/E move
- 18.3%
- Pseudo strike
- 10.05
- IV
- 259.4%
- B/E move
- 9.4%
65Δ
- Pseudo strike
- 7.66
- IV
- 351.7%
- B/E move
- 17.8%
- Pseudo strike
- 10.43
- IV
- 244.5%
- B/E move
- 8.1%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.80
- IV
- 229.6%
- B/E move
- 6.7%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.18
- IV
- 214.7%
- B/E move
- 5.4%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.55
- IV
- 199.8%
- B/E move
- 4.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 99.57% | |
| 81.08% | |
| 95.35% | |
| 88.94% | |
| 116.95% | |
| 112.56% | |
| 101.99% | |
| 80.32% |
Biotechnology
PCVX
Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City,…
More →PDSB
PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. The company is headquartered in Florham…
More →PEPG
PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and…
More →PGEN
Description unavailable
More →PHAT
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is…
More →PHVS
Description unavailable
More →